NCT01242917 - A Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy | Biotech Hunter

Enrollment

159

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions

Rheumatoid Arthritis

Interventions

DRUG

CCX-354-C

200mg film-coated tablets once daily for 12 weeks + Methotrexate

DRUG

Placebo

Placebo film-coated tablets twice daily for 12 weeks + methotrexate

DRUG

CCX354-C

100mg film-coated tablets twice daily for 12 weeks + methotrexate

Trial Locations (41)

Unknown

Brussels

Kortrijik

Liège

Brno

Bruntál

Hlučín

Ostrava-Trebovice

Prague

Uherské Hradiště

Zlín

Berlin

Frankfurt

Hanover

Herne

Leipzig

Mainz

Würzburg

Balatonfüred

Békéscsaba

Budapest

Székesfehérvár

Veszprém

Amsterdam

Chełm Śląski

Elblag

Grodzisk Mazowiecki

Krakow

Lublin

Poznan

Warsaw

Żyrardów

Bacau

Baia Mare

Brăila

Bucharest

Galati

Saint Gheorghe, Covasna

Târgovişte

Donetsk

Kharkiv

Kiev